+ 0.75
+ 0.22%

These ETFs House The Next Biotech Takeover Targets

August 26, 2013 7:44 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Big news out of the biotechnology sector Monday as Amgen (NASDAQ: AMGN) has finally reached an agreement to acquire Onyx Pharmaceuticals (NASDAQ: ONXX) for $10.4 billion, or $125 per share. Amgen has long been pursuing Onyx so the former can bolster its lineup of cancer therapies.

Related: ETFs For An Onyx Takeover Battle.

It is easy to understand why Amgen tried so diligently to get its hands on Onyx. Cancer therapies are big business for biotech and traditional pharmaceuticals firms. In 2012, cancer drugs accounted for $84 billion in world-wide sales, second only to central nervous system treatments, the Wall Street Journal reported, citing EvaluatePharma.

Expect more biotech sector mergers and acquisitions activity focused on cancer drugs. About a quarter of industry deals greater than $100 million now involve cancer, more than any other disease, the Journal reported, citing J.P. Morgan Chase.

Some of the companies that could now enter the spotlight on news of Onyx being acquired include Celledex Therapeutics (NASDAQ: CLDX) and Ariad Pharmaceuticals (NASDAQ: ARIA). Celledex focuses on development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases, according to Minyanville.

Ariad is working on blood cancer and tumor therapies. Combined, the two companies do not even have a market value of $5.3 billion, indicating they could be had prices that cash-rich large-cap biotech and blue-chip pharma companies could easily digest.

The two stocks combine for 4.3 percent of the SPDR S&P Biotech ETF's (NYSE: XBI) weight. Onyx is also a top-10 holding in that ETF.

Array BioPharma (NASDAQ: ARRY) and Clovis Oncology (NASDAQ: CLVS) are two more cancer drug stocks residing in XBI that dwell nowhere near large-cap territory. Same goes for XBI holding Exact Sciences (NASDAQ: EXAS), another cancer drug stock. That trio represents nearly four percent of the ETF's weight.

Another ETF investors should monitor if biotech sector M&A heats up in earnest is not a health care fund at all. However, the PowerShares DWA SmallCap Technical Leaders Portfolio (NYSE: DWAS) does allocate 19.3 percent of its weight to the health care sector, second only to its 26 percent weight to discretionary names. More importantly, DWAS has a penchant for outperforming some larger small-cap ETFs.

Even for high-flying small-cap ETFs, it is hard to top the 29.6 percent DWAS has returned this year. Overall, DWAS is home to 35 health care stocks including Celledex and Clovis. Endocyte (NASDAQ: ECYT) is another maker of cancer therapies and is also found in the DWAS lineup.

Isis Pharmaceuticals (NASDAQ: ISIS) is one of the smallest DWAS health care components, but the company has potential exposure to the cancer drug boom and has previously been mentioned as a possible takeover target.

For more on ETFs, click here.

Related Articles

Is Silicon Valley Replacing Big Pharma In Neuroscience?

The following article is sponsored by Mind Cure. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. read more

The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 30) read more

Amgen Bets On Regenerative Immunology With Rodeo Therapeutics Acquisition

With blockbuster immunology treatments Enbrel (via $16 billion acquisition of Immunex in 2009) and Otezla (added in 2013 via $13 billion deal) already in its bag, Amgen Inc (NASDAQ: AMGN) read more

Though Potential Bidders Moved Away, Amgen's Bid For Five Prime Outlasted 15 Suitors

Earlier this month, biotech giant Amgen Inc (NASDAQ: AMGN)  read more